Department of Pharmacology

Faculty

< Return to faculty list.

Michael R. Wood, Ph.D.

Research Assistant Professor of Chemistry
Research Assistant Professor of Pharmacology
BRET Profile (opens in a new window)
michael.r.wood@Vanderbilt.Edu
(615) 322-0670
12415C MRB IV (Langford)
Nashville, TN 37232-0697

Education

NIH Postdoctoral Research Fellow, Harvard University, Cambridge, MA
Ph.D., University of California, Santa Barbara, CA
B.S., California State University Chico, Chico, CA

Research Keywords

Muscarinic Receptors Schizophrenia Alzheimer's Disease Medicinal Chemistry Drug Development CNS disorders

Research Description

As a faculty member in the departments of Pharmacology and Chemistry at Vanderbilt University, and a member of the VCNDD, I partition my time between the direction of research activities around the family of muscarinic receptors (VCNDD) and activities associated with the MLPCN Roadmap initiative (NIH). While focusing primarily on the muscarinic M1 and M4 subtypes I have helped direct the discovery of novel chemical entities with improved physical properties or improved receptor subtype selectivity for M1 antagonists and a number of M1 PAMs, M4 PAMs and M5 PAMs. These molecules will enable our pharmacology colleagues to explore and better understand the function of the muscarinic receptors in both healthy and diseased states with the ultimate goal of making a direct impact on human health. My work in conjunction with the MLPCN has allows me to interact with a wide range of collaborators (Vanderbilt, UNM, NCGC and SRI) across a variety of projects ranging from Protein-Protein Interactions (PPI), to allosteric modulators of glutamate (mGlu8) and muscarinic receptors and even into more phenotypic projects using high-content flow cytometry to explore immune responses (LFA and VLA-4) and multi-drug resistant efflux pumps. A primary goal of these efforts is to provide the scientific community with novel and high quality probe molecules where previously there had been none or to provide superior research tools as compared to the present state of the art. These MLPCN projects serve as ideal training opportunities for both graduate and post-graduate colleagues and have allowed me to interact with and mentor developing scientists at all levels.

Publications

Salovich, JM, Vinson, PN, Sheffler, DJ, Lamsal, A, Utley, TJ, Blobaum, AL, Bridges, TM, Le, U, Jones, CK, Wood, MR, Scott Daniels, J, Jeffrey Conn, P, Niswender, CM, Lindsley, CW, Hopkins, CR. Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M(4)) receptor. Bioorg Med Chem Lett, 2012

Melancon, BJ, Utley, TJ, Sevel, C, Mattmann, ME, Cheung, YY, Bridges, TM, Morrison, RD, Sheffler, DJ, Niswender, CM, Scott Daniels, J, Jeffrey Conn, P, Lindsley, CW, Wood, MR. Development of novel M(1) antagonist scaffolds through the continued optimization of the MLPCN probe ML012. Bioorg Med Chem Lett, 2012

Melancon, BJ, Gogliotti, RD, Tarr, JC, Saleh, SA, Chauder, BA, Lebois, EP, Cho, HP, Utley, TJ, Sheffler, DJ, Bridges, TM, Morrison, RD, Daniels, JS, Niswender, CM, Conn, PJ, Lindsley, CW, Wood, MR. Continued optimization of the MLPCN probe ML071 into highly potent agonists of the hM1 muscarinic acetylcholine receptor. Bioorg Med Chem Lett, 22(10), 3467-72, 2012

Bubser, M, Byun, N, Wood, MR, Jones, CK. Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Handb Exp Pharmacol(208), 121-66, 2012

Melancon, BJ, Lamers, AP, Bridges, TM, Sulikowski, GA, Utley, TJ, Sheffler, DJ, Noetzel, MJ, Morrison, RD, Scott Daniels, J, Niswender, CM, Jones, CK, Conn, PJ, Lindsley, CW, Wood, MR. Development of a more highly selective M(1) antagonist from the continued optimization of the MLPCN Probe ML012. Bioorg Med Chem Lett, 22(2), 1044-8, 2012

Melancon, BJ, Hopkins, CR, Wood, MR, Emmitte, KA, Niswender, CM, Christopoulos, A, Conn, PJ, Lindsley, CW. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem, 55(4), 1445-64, 2012

Lebois, EP, Digby, GJ, Sheffler, DJ, Melancon, BJ, Tarr, JC, Cho, HP, Miller, NR, Morrison, R, Bridges, TM, Xiang, Z, Scott Daniels, J, Wood, MR, Conn, PJ, Lindsley, CW. Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg Med Chem Lett, 21(21), 6451-5, 2011

Wood, MR, Hopkins, CR, Brogan, JT, Conn, PJ, Lindsley, CW. &quot;Molecular switches&quot; on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry, 50(13), 2403-10, 2011

Reid, PR, Bridges, TM, Sheffler, DJ, Cho, HP, Lewis, LM, Days, E, Daniels, JS, Jones, CK, Niswender, CM, Weaver, CD, Conn, PJ, Lindsley, CW, Wood, MR. Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe. Bioorg Med Chem Lett, 21(9), 2697-701, 2011

Bridges, TM, LeBois, EP, Hopkins, CR, Wood, MR, Jones, CK, Conn, PJ, Lindsley, CW. The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect, 23(4), 229-40, 2010

Wood, MR, Schirripa, KM, Kim, JJ, Bednar, RA, Fay, JF, Bruno, JG, Moore, EL, Mosser, SD, Roller, S, Salvatore, CA, Vacca, JP, Selnick, HG. Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality. Bioorg Med Chem Lett, 20(22), 6827-30, 2010

Wood, MR, Schirripa, KM, Kim, JJ, Quigley, AG, Stump, CA, Bell, IM, Bednar, RA, Fay, JF, Bruno, JG, Moore, EL, Mosser, SD, Roller, S, Salvatore, CA, Kane, SA, Vacca, JP, Selnick, HG. Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibility. Bioorg Med Chem Lett, 19(19), 5787-90, 2009

Wood, MR, Schirripa, KM, Kim, JJ, Kuduk, SD, Chang, RK, Di Marco, CN, DiPardo, RM, Wan, BL, Murphy, KL, Ransom, RW, Chang, RS, Holahan, MA, Cook, JJ, Lemaire, W, Mosser, SD, Bednar, RA, Tang, C, Prueksaritanont, T, Wallace, AA, Mei, Q, Yu, J, Bohn, DL, Clayton, FC, Adarayn, ED, Sitko, GR, Leonard, YM, Freidinger, RM, Pettibone, DJ, Bock, MG. Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonists. Bioorg Med Chem Lett, 18(2), 716-20, 2008

Kuduk, SD, Di Marco, CN, Chang, RK, Wood, MR, Schirripa, KM, Kim, JJ, Wai, JM, DiPardo, RM, Murphy, KL, Ransom, RW, Harrell, CM, Reiss, DR, Holahan, MA, Cook, J, Hess, JF, Sain, N, Urban, MO, Tang, C, Prueksaritanont, T, Pettibone, DJ, Bock, MG. Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists. J Med Chem, 50(2), 272-82, 2007

Kuduk, SD, Di Marco, CN, Chang, RK, Wood, MR, Kim, JJ, Schirripa, KM, Murphy, KL, Ransom, RW, Tang, C, Torrent, M, Ha, S, Prueksaritanont, T, Pettibone, DJ, Bock, MG. 5-Piperazinyl pyridine carboxamide bradykinin B1 antagonists. Bioorg Med Chem Lett, 16(10), 2791-5, 2006

Wood, MR, Kim, JJ, Han, W, Dorsey, BD, Homnick, CF, DiPardo, RM, Kuduk, SD, MacNeil, T, Murphy, KL, Lis, EV, Ransom, RW, Stump, GL, Lynch, JJ, O''Malley, SS, Miller, PJ, Chen, TB, Harrell, CM, Chang, RS, Sandhu, P, Ellis, JD, Bondiskey, PJ, Pettibone, DJ, Freidinger, RM, Bock, MG. Benzodiazepines as potent and selective bradykinin B1 antagonists. J Med Chem, 46(10), 1803-6, 2003